The DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index.
Tumor formation and inactivation of RIZ1, an Rb-binding member of a nuclear protein-methyltransferase superfamily
Open accessAbstract
The retinoblastoma protein-interacting zinc finger gene RIZ (PRDM2) is a member, by sequence homology, of a nuclear protein-methyltransferase (MTase) superfamily involved in chromatin-mediated gene expression. The gene produces two protein products, RIZ1 that contains a conserved MTase domain and RIZ2 that lacks the domain. RIZ1 gene expression is frequently silenced in human cancers, and the gene is also a common target of frameshift mutation in microsatellite-unstable cancers. We now report studies of mice with a targeted mutation in the RIZ1 locus. The mutation inactivates RIZ1 but not RIZ2. These RIZ1 mutant mice were viable and fertile but showed a high incidence of diffuse large B-cell lymphomas (DLBL) and a broad spectrum of unusual tumors. RIZ1 deficiency also accelerated tumorigenesis in p53 heterozygous mutant mice. Finally, several missense mutations of RIZ1 were found in human tumor tissues and cell lines; one of these was particularly common in human DLBL tumors. These missense mutations, as well as the previously described frameshift mutation, all mapped to the MTase functional domains. All abolished the capacity of RIZ1 to enhance estrogen receptor activation of transcription. These data suggest a direct link between tumor formation and the MTase domain of RIZ1 and describe for the first time a tumor susceptibility gene among methyltransferases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, Rb can interact with other histone methyltransferases (Steele-Perkins et al., 2001)”
From Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence (2003) · cites this paper as Steele-Perkins et al., 2001
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutation and cancer: statistical study of retinoblastoma
Knudson, A. G. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.4.820 · Cited by 7,612
Beighton, P., & Beighton, G. (1997) · Springer eBooks · doi:10.1007/978-1-4471-0925-9_118 · Cited by 3,165
Landis, S., Murray, T., Bolden, S., & Wingo, P. A. (1999) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.49.1.8 · Cited by 3,068
Regulation of chromatin structure by site-specific histone H3 methyltransferases
Rea, S., Eisenhaber, F., O'Carroll, D., Strahl, B. D., Sun, Z.-W., Schmid, M., Opravil, S., Mechtler, K., Ponting, C. P., Allis, C. D., et al. (2000) · Nature · doi:10.1038/35020506 · Cited by 2,845
Cancer-epigenetics comes of age
Jones, P. A., & Laird, P. W. (1999) · Nature Genetics · doi:10.1038/5947 · Cited by 2,358
Tumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051
Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice
Soriano, P. M., Montgomery, C. A., Geske, R. S., & Bradley, A. (1991) · Cell · doi:10.1016/0092-8674(91)90499-o · Cited by 1,997
Mansour, S. L., Thomas, K. R., & Capecchi, M. R. (1988) · Nature · doi:10.1038/336348a0 · Cited by 1,683
DNA hypermethylation in tumorigenesis: epigenetics joins genetics
Baylin, S. B., & Herman, J. G. (2000) · Trends in Genetics · doi:10.1016/s0168-9525(99)01971-x · Cited by 1,615
Regulation of Transcription by a Protein Methyltransferase
Chen, D., Ma, H., Hong, H., Koh, S. S., Huang, S., Schurter, B. T., Aswad, D. W., & Stallcup, M. R. (1999) · Science · doi:10.1126/science.284.5423.2174 · Cited by 1,214
Flagged first, then by citations
2 of the 52 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
The history of cancer epigenetics
Feinberg, A. P., & Tycko, B. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1279 · Cited by 2,404
“Interestingly, the Riz1 gene, which encodes a histone methyltransferase that can associate with Rb, was found by Huang and colleagues to sometimes be inactivated epigenetically and act as a tumour suppressor in mic”
BackgroundRb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence
Narita, M., Nuñez, S., Heard, E., Narita, M., Lin, A. W., Hearn, S. A., Spector, D. L., Hannon, G. J., & Lowe, S. W. (2003) · Cell · doi:10.1016/s0092-8674(03)00401-x · Cited by 2,278
Writing, erasing and reading histone lysine methylations
Hyun, K., Jeon, J., Park, K., & Kim, J. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.11 · Cited by 1,250
Oncogene-induced senescence as an initial barrier in lymphoma development
Braig, M., Lee, S., Loddenkemper, C., Rudolph, C., Peters, A. H. F. M., Schlegelberger, B., Stein, H., Dörken, B., Jenuwein, T., & Schmitt, C. A. (2005) · Nature · doi:10.1038/nature03841 · Cited by 1,220
Histone methylation in transcriptional control
Kouzarides, T. (2002) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(02)00287-3 · Cited by 908
Lund, A. H., & van Lohuizen, M. (2004) · Genes & Development · doi:10.1101/gad.1232504 · Cited by 489
“Interestingly, only RIZ1 harbors a SET domain and appears to be the main target of inactivation in tumors (Huang 2002), and mice lacking Riz1 function only are prone to tumor formation (Steele-Perkins et al. 2001).”
BackgroundGarcía-Bassets, I., Kwon, Y., Telese, F., Préfontaine, G. G., Hutt, K. R., Cheng, C. S., Ju, B., Ohgi, K. A., Wang, J., Escoubet‐Lozach, L., et al. (2007) · Cell · doi:10.1016/j.cell.2006.12.038 · Cited by 438
Chromatin remodeling and cancer, part I: covalent histone modifications
Wang, G. G., Allis, C. D., & Chi, P. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.07.003 · Cited by 422
“Furthermore, missense mutations that abolish the HMT activity of RIZ1 are found in human cancers [37, 39 ], suggesting a direct causal effect Table 1. Examples of histone methylation and cancer Classes of histone modification Histone-modifying enzymes and binding”
BackgroundHistone lysine methylation and demethylation pathways in cancer
Varier, R. A., & Timmers, H. T. M. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.10.002 · Cited by 351
Epigenetics—An Epicenter of Gene Regulation: Histones and Histone‐Modifying Enzymes
Biel, M., Wascholowski, V., & Giannis, A. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200461346 · Cited by 324
Histone methyltransferases in cancer
Albert, M., & Helin, K. (2009) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2009.10.007 · Cited by 320
“M Diffuse B-cell lymphoma (DBCL) Knockout mice [158]”
BackgroundUnsafe SETs: histone lysine methyltransferases and cancer
Schneider, R., Bannister, A. J., & Kouzarides, T. (2002) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(02)02141-2 · Cited by 287
The prdm family: expanding roles in stem cells and development
Hohenauer, T., & Moore, A. W. (2012) · Development · doi:10.1242/dev.070110 · Cited by 265
“They also include the enzyme Prmt5 (protein methyltransferase 5), which methylates arginines to create a repressive state, and Lsd1 (lysinespecific demethylase 1, Kdm1a), which primarily promotes repression through erasure of activating H3K4 (histone H3 lysine 4) methylation marks.”
BackgroundInfluentialYeung, M. L., Houzet, L., Yedavalli, V. S. R. K., & Jeang, K. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.010033 · Cited by 263
Cancer genetics of epigenetic genes
Miremadi, A., Oestergaard, M. Z., Pharoah, P. D. P., & Caldas, C. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm021 · Cited by 255
“Targeted inactivating mutations of PRDM2 in mice are associated with development of large B-cell lymphoma and a range of unusual tumors (168).”
BackgroundMutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas
Tam, W., Gomez, M. F., Chadburn, A., Lee, J. W., Chan, W. C., & Knowles, D. M. (2006) · Blood · doi:10.1182/blood-2005-09-3778 · Cited by 229
Dynamic protein methylation in chromatin biology
Ng, S. S., Yue, W. W., Oppermann, U. C. T., & Klose, R. J. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8303-z · Cited by 250
Methylation of the Retinoblastoma Tumor Suppressor by SMYD2
Saddic, L., West, L. E., Aslanian, A., Yates, J. R., Rubin, S. M., Gozani, O., & Sage, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.137612 · Cited by 226
A Macrohistone Variant Links Dynamic Chromatin Compaction to BRCA1-Dependent Genome Maintenance
Khurana, S., Kruhlak, M. J., Kim, J., Tran, A. D., Liu, J., Nyswaner, K., Shi, L., Jailwala, P., Sung, M.-H., Hakim, O., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.07.024 · Cited by 220
“PRDM2 is a PR/SET domain protein and has been implicated in tumor suppression in mice and humans (Kim et al., 2003; Steele-Perkins et al., 2001).”
BackgroundSelf-citationPRDM proteins: important players in differentiation and disease
Fog, C. K., Galli, G. G., & Lund, A. H. (2012) · BioEssays · doi:10.1002/bies.201100107 · Cited by 201
“Abbreviations: ABC, activated B cell-like; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CLP, common lymphoid progenitor; CML, chronic myeloid leukemia; CMP, common myeloid progenitor; DLBCL, diffuse large B cell lymphoma; ES, embryonic stem; GC, germinal center; HA…”
BackgroundInfluentialLiu, G., Bollig-Fischer, A., Kreike, B., van de Vijver, M., Abrams, J., Ethier, S., & Yang, Z.-Q. (2009) · Oncogene · doi:10.1038/onc.2009.297 · Cited by 208
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript and a broad spectrum of unusual tumors (Steele-Perkins et al., 2001).”
BackgroundInfluentialThe control of histone lysine methylation in epigenetic regulation
Völkel, P., & Angrand, P. (2006) · Biochimie · doi:10.1016/j.biochi.2006.07.009 · Cited by 213
Iacobuzio–Donahue, C. A. (2008) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev.pathol.3.121806.151442 · Cited by 188
Inactivation of a histone methyltransferase by mutations in human cancers.
Kim, K., Geng, L., & Huang, S. (2003) · PubMed · Cited by 184
Du, Y., Carling, T., Fang, W., Piao, Z. H., Sheu, J., & Huang, S. (2001) · PubMed · Cited by 170
Epigenetic regulation of normal and malignant hematopoiesis
Rice, K. L., Hormaeche, I., & Licht, J. D. (2007) · Oncogene · doi:10.1038/sj.onc.1210755 · Cited by 161
“RIZ1 knockout mice develop B-cell lymphoma (Steele-Perkins et al., 2001), and in chronic myelogenous leukemia (CML), blastic transformation is associated with loss of heterozygosity in the vicinity of RIZ1 and a decrease in RIZ1 expression (Pastural et al., 2007).”
BackgroundHistone modifying and chromatin remodelling enzymes in cancer and dysplastic syndromes
Gibbons, R. J. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi106 · Cited by 155
“Furthermore, gene knockout mice that lack RIZ1 are prone to develop B cell lymphomas (30).”
BackgroundHistone methyltransferases, diet nutrients and tumour suppressors
Huang, S. (2002) · Nature reviews. Cancer · doi:10.1038/nrc819 · Cited by 150
Oncogene- and tumor suppressor gene-mediated suppression of cellular senescence
Larsson, L. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.10.005 · Cited by 152
“Although spontaneous alterations in UV39H1 have not been documented in human tumors, another Rb-binding HMT, RIZ1, is frequently silenced or mutated in uman cancers, and targeted mutation of RIZ1 in mice results in ymphomagenesis [36].”
BackgroundNishikata, I., Sasaki, H., Iga, M., Tateno, Y., Imayoshi, S., Asou, N., Nakamura, T., & Morishita, K. (2003) · Blood · doi:10.1182/blood-2002-12-3944 · Cited by 145
Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice
You, M. J., Castrillón, D. H., Bastian, B. C., O’Hagan, R. C., Bosenberg, M., Parsons, R. E., Chin, L., & DePinho, R. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.022632099 · Cited by 143
BLIMP1 guides the fate of effector B and T cells
Nutt, S. L., Fairfax, K. A., & Kallies, A. (2007) · Nature reviews. Immunology · doi:10.1038/nri2204 · Cited by 139
Fumasoni, I., Meani, N., Rambaldi, D., Scafetta, G., Alcalay, M., & Ciccarelli, F. D. (2007) · BMC Evolutionary Biology · doi:10.1186/1471-2148-7-187 · Cited by 139
“All these genes can code for both a full-length protein and an isoform without the PR-domain, which is often overexpressed in cancer [22,23].”
Nanjundan, M., Nakayama, Y., Cheng, K. W., Lahad, J. P., Liu, J., Lu, K., Kuo, W.-L., Smith‐McCune, K., Fishman, D. A., Gray, J. W., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2366 · Cited by 133
“EVI1, which has the potential to act as a protein methyltransferase (32).”
BackgroundGyőry, I., Fejér, G., Ghosh, N., Seto, E., & Wright, K. L. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.6.3125 · Cited by 130
“The recent development of mice with normal expression of RIZ2, but a selective disruption of the RIZ1 isoform, confirms a role in tumor development (20).”
BackgroundRobertson, E. J., Charatsi, I., Joyner, C. J., Koonce, C. H., Morgan, M., Islam, A., Paterson, C. A., Lejsek, E., Arnold, S. J., Kallies, A., et al. (2007) · Development · doi:10.1242/dev.012047 · Cited by 127
Greenwood, E. (2001) · Nature reviews. Cancer · doi:10.1038/35094036 · Cited by 120
Methyl Deficiency, Alterations in Global Histone Modifications, and Carcinogenesis
Pogribny, I. P., Tryndyak, V., Muskhelishvili, L., Rusyn, I., & Ross, S. A. (2007) · Journal of Nutrition · doi:10.1093/jn/137.1.216s · Cited by 118
An expanding job description for Blimp-1/PRDM1
Bikoff, E. K., Morgan, M. A., & Robertson, E. J. (2009) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.05.005 · Cited by 108
Epigenetic regulation of development by histone lysine methylation
Dambacher, S., Hahn, M., & Schotta, G. (2010) · Heredity · doi:10.1038/hdy.2010.49 · Cited by 109
“(2003) Viable Tumorigenesis (Steele-Perkins et al., 2001) Prdm3 E13.”
PRDM5 is silenced in human cancers and has growth suppressive activities
Deng, Q., & Huang, S. (2004) · Oncogene · doi:10.1038/sj.onc.1207615 · Cited by 102
“Deficiency in the PR-domain of PRDM2 causes tumor susceptibility in mice and mutations in this domain are present in human cancers (Steele-Perkins et al., 2001; Kim et al., 2003).”
BackgroundThe role of PRDMs in cancer: one family, two sides
Mzoughi, S., Tan, Y. X., Low, D. H. P., & Guccione, E. (2016) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2016.03.009 · Cited by 104
Histone Modifications in Cancer Biology and Prognosis
Kurdistani, S. K. (2010) · Springer eBooks · doi:10.1007/978-3-7643-8989-5_5 · Cited by 106
Yoshida, M., Nosaka, K., Yasunaga, J., Nishikata, I., Morishita, K., & Matsuoka, M. (2003) · Blood · doi:10.1182/blood-2003-07-2482 · Cited by 100
Hickabottom, M., Parker, G. A., Freemont, P. S., Crook, T., & Allday, M. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m208116200 · Cited by 92
PRDM Proteins: Molecular Mechanisms in Signal Transduction and Transcriptional Regulation
Zazzo, E. D., Rosa, C. D., Abbondanza, C., & Moncharmont, B. (2013) · Biology · doi:10.3390/biology2010107 · Cited by 91
“This would explain why the PRDM2 (PR-minus) form is unable to produce enhancer effects in presence of estradiol, as observed with ERE-Luc reporter assay experiments in vitro [39], despite the presence of domains for the recruitment of p300 and p160 co-activators [34].”
BackgroundTIP30 deficiency increases susceptibility to tumorigenesis.
Ito, M., Jiang, C. Y., Krumm, K., Zhang, X., Pecha, J., Zhao, J., Guo, Y., Roeder, R. G., & Xiao, H. (2003) · PubMed · Cited by 90
Genetic and epigenetic changes in sporadic endocrine tumors: Parathyroid tumors
Costa‐Guda, J., & Arnold, A. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.09.005 · Cited by 89
“However, aberrant expression of RIZ1 has not been reported in parathyroid tumors and loss of RIZ1 does not appear to be able to drive parathyroid tumor development in genetically engineered mice (Steele-Perkins et al., 2001).”
Regulation of transcription and chromatin structure by pRB: Here, there and everywhere
Talluri, S., & Dick, F. A. (2012) · Cell Cycle · doi:10.4161/cc.21263 · Cited by 91
Dick, F. A. (2007) · Cell Division · doi:10.1186/1747-1028-2-26 · Cited by 79
Mutations and epimutations in the origin of cancer
Peltomäki, P. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.12.001 · Cited by 88
Yang, Z., Jones, A., Widschwendter, M., & Teschendorff, A. E. (2015) · Genome biology · doi:10.1186/s13059-015-0699-9 · Cited by 83
“In agreement with previous studies, PRDM2 has been found to be widely underexpressed in epithelial [68] and hematological cancers [69].”
ResultThe genetic pathogenesis of colorectal cancer
Lynch, J. P., & Hoops, T. C. (2002) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(02)00029-1 · Cited by 78
Keynote review: Chromatin control and cancer-drug discovery: realizing the promise
Inche, A. G., & Thangue, N. B. L. (2006) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03691-3 · Cited by 77
Multifaceted Role of PRDM Proteins in Human Cancer
Casamassimi, A., Rienzo, M., Zazzo, E. D., Sorrentino, A., Fiore, D., Proto, M., Moncharmont, B., Gazzerro, P., Bifulco, M., & Abbondanza, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072648 · Cited by 76
“Indeed, an accelerated tumorigenesis was associated with Riz1 deficiency (Riz1-/-) on the p53+/- background [55].”
BackgroundA Histone Methyltransferase Is Required for Maximal Response to Female Sex Hormones
Carling, T., Kim, K., Yang, X. H., Gu, J., Zhang, X.-K., & Huang, S. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.16.7032-7042.2004 · Cited by 72
“vectors and RIZ1 mutant vectors have been described (42).”
BackgroundMethodInfluentialChittka, A., Arévalo, J. C., Rodriguez-Guzman, M., Pérez, P., Chao, M. V., & Sendtner, M. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200301106 · Cited by 71
“Thus, transcriptional activities of repressive and activating nature have been described for RIZ (Xie et al., 1997; Abbondanza et al., 2000; Steele-Perkins et al., 2001), Blimp-1/PRDI-BF1 (Lin et al., 1997; Ren et al., 1999; Yu et al., 2000), and Evi-1 (Kurokawa et al., 1998; Izutsu et al., 2001; Palmer et al., 2001).”
BackgroundInfluentialHistone Modification Therapy of Cancer
Biancotto, C., Frigè, G., & Minucci, S. (2010) · Advances in genetics · doi:10.1016/b978-0-12-380866-0.60013-7 · Cited by 74
MacDonald, J. I., & Dick, F. A. (2012) · Genes & Cancer · doi:10.1177/1947601912473305 · Cited by 71
The duality of PRDM proteins: epigenetic and structural perspectives
Tullio, F. D., Schwarz, M. C., Zorgati, H., Mzoughi, S., & Guccione, E. (2021) · FEBS Journal · doi:10.1111/febs.15844 · Cited by 70
Frequent epigenetic inactivation of RIZ1 by promoter hypermethylation in human gastric carcinoma
Oshimo, Y., Oue, N., Mitani, Y., Nakayama, H., Kitadai, Y., Yoshida, K., Chayama, K., & Yasui, W. (2004) · International Journal of Cancer · doi:10.1002/ijc.20090 · Cited by 66
Targeting the epigenome for treatment of cancer
Geutjes, E.-J., Bajpe, P. K., & Bernards, R. (2011) · Oncogene · doi:10.1038/onc.2011.552 · Cited by 62
“KMT8 can be silenced by promoter hyper-methylation; is located on the frequently deleted 1p36 chromosomal locus; and is subject to PR domain-targeting loss-offunction mutations (He et al., 1998; Chadwick et al., 2000; Steele-Perkins et al., 2001).”
BackgroundInfluentialCheedipudi, S. M., Puri, D., Saleh, A., Gala, H., Rumman, M., Pillai, M. S., Sreenivas, P., Arora, R., Sellathurai, J., Schrøder, H. D., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv567 · Cited by 60
“Of the PRDM2 isoforms, RIZ1 (an H3K9 methyl transferase, (38,39) is deleted in cancers, but RIZ2, which lacks the PR domain, is not; targeted deletion of just RIZ1 increased tumor incidence (40).”
BackgroundPastural, É., Takahashi, N., Dong, W.-F., Bainbridge, M. N., Hull, A. R., Pearson, D., Huang, S., Lowsky, R., DeCoteau, J. F., & Geyer, C. R. (2006) · Oncogene · doi:10.1038/sj.onc.1209959 · Cited by 58
“RIZ1 / mice have a high incidence of diffuse large B-cell lymphoma and a broad spectrum of unusual tumors (Steele-Perkins et al., 2001).”
BackgroundBiallelic inactivation of the RIZ1 gene in human gastric cancer
Tokumaru, Y., Nomoto, S., Jerónimo, C., Henrique, R., Harden, S., Trink, B., & Sidransky, D. (2003) · Oncogene · doi:10.1038/sj.onc.1206403 · Cited by 58
Carling, T., Du, Y., Fang, W., Correa, P., & Huang, S. (2003) · Surgery · doi:10.1016/s0039-6060(03)00422-7 · Cited by 57
Chapter 4 Histone Demethylases and Cancer
Kampranis, S. C., & Tsichlis, P. N. (2009) · Advances in cancer research · doi:10.1016/s0065-230x(09)02004-1 · Cited by 56
“…Huang (2004), Du et al. (2005), Hasegawa et al. (2007), Kim et al. (2003), Lakshmikuttyamma et al. (2008), Lal et al. (2006), Piao et al. (2008), Steele-Perkins et al. (2001), Yoon et al. (2007) EZH2/KMT6 Overexpressed in a variety of human tumors, including aggressive prostate and breast…”
BackgroundThe Role of Histone Modifications and Variants in Regulating Gene Expression in Breast Cancer
Dalvai, M., & Bystricky, K. (2010) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-010-9167-z · Cited by 58
Reclassification of oligoastrocytomas by loss of heterozygosity studies
Eoli, M., Bissola, L., Bruzzone, M. G., Pollo, B., Maccagnano, C., Simone, T. D., Valletta, L., Silvani, A., Bianchessi, D., Broggi, G., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.21759 · Cited by 55
“ferase superfamily involved in chromatin-mediated gene expression.(24) RIZ1 mutations were not detected in 40 oligodendrogliomas,(25) but investigations on its expression, that in other tumors can be decreased by promoter methylation or haplotype insufficiency,(26) should be performed before ruling out its involvement…”
BackgroundCharacterization of the PR domain of RIZ1 histone methyltransferase
Derunes, C., Briknarová, K., Geng, L., Li, S., Gessner, C. R., Hewitt, K. M., Wu, S., Huang, S., Woods, V. I., & Ely, K. R. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.05.190 · Cited by 54
Histone modifications as a pathogenic mechanism of colorectal tumorigenesis
Gargalionis, A. N., Piperi, C., Adamopoulos, C., & Papavassiliou, A. G. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.05.002 · Cited by 53
RIZ1 is epigenetically inactivated by promoter hypermethylation in thyroid carcinoma
Lal, G., Padmanabha, L., Smith, B. J., Nicholson, R. M., Howe, J. R., O'Dorisio, M. S., & Domann, F. E. (2006) · Cancer · doi:10.1002/cncr.22325 · Cited by 52
“In tumors characterized by chromosomal instability, inactivation of RIZ1 is related to allelic loss and epigenetic silencing involving promoter hypermethylation, whereas mutations are rare.(9,11,16) Promoter hypermethylation has been shown to be associated with reduced RIZ1 expression in solid tumors, such as gastric(…”
BackgroundPRDM15 is a key regulator of metabolism critical to sustain B-cell lymphomagenesis
Mzoughi, S., Fong, J. Y., Papadopoli, D. J., Koh, C. M., Hulea, L., Pigini, P., Tullio, F. D., Andreacchio, G., Hoppe, M. M., Wollmann, H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17064-0 · Cited by 53
Chang, H. W., Chan, A., Kwong, D. L. �., Wei, W., Sham, J. S. T., & Yuen, A. P. W. (2003) · PubMed · Cited by 49
The Retinoblastoma Gene Family in Cell Cycle Regulation and Suppression of Tumorigenesis
Dannenberg, J.-H., & te Riele, H. P. J. (2006) · Results and Problems in Cell Differentiation · doi:10.1007/400_002 · Cited by 47
Methylation profiling in multiple myeloma
Chim, C. S., Kwong, Y., Fung, T. K., & Liang, R. H. S. (2003) · Leukemia Research · doi:10.1016/j.leukres.2003.08.008 · Cited by 47
“acid receptor beta (RARβ), retinoblastoma protein-binding zinc finger protein (RIZ1), and von Hippel-Lindau (VHL)), [2,4,7,8,10,11] apoptosis (death-associated protein kinase (DAPK)), [12,13] and cell adhesion (E-cadherin (E-CAD)) [14].”
BackgroundAltered expression of retinoblastoma protein‐interacting zinc finger gene, RIZ, in human leukaemia
Sasaki, O., Meguro, K., Tohmiya, Y., Funato, T., Shibahara, S., & Sasaki, T. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03972.x · Cited by 46
“…et al, 1998; Jiang et al, 1999; Chadwick et al, 2000; Gazzerro et al, 2001), and the RIZ1 gene knock-out studies in mice, demonstrating a high incidence of a broad spectrum of tumours including diffuse large B-cell lymphomas (Steele-Perkins et al, 2001), suggest tumour suppressor activity by RIZ1.”
BackgroundInfluentialLinking Covalent Histone Modifications to Epigenetics: The Rigidity and Plasticity of the MarksPreprint
Wang, Y., Wysocka, J., Perlin, J. R., Leonelli, L., Allis, C. D., & Coonrod, S. A. (2004) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2004.69.161 · Cited by 42
Epigenetik – ein Epizentrum der Genregulation: Histone und histonmodifizierende Enzyme
Biel, M., Wascholowski, V., & Giannis, A. (2005) · Angewandte Chemie · doi:10.1002/ange.200461346 · Cited by 42
Leukemogenesis of the EVI1/MEL1 Gene Family
Morishita, K. (2007) · International Journal of Hematology · doi:10.1532/ijh97.06174 · Cited by 41
“The PR domain of the PRDM gene family is a subclass of the SET domain, which is most closely related to the known histone methyltransferases [ 32 ].”
BackgroundGazzerro, P., Abbondanza, C., D'Arcangelo, A., Rossi, M., Medici, N., Moncharmont, B., & Puca, G. A. (2005) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.11.002 · Cited by 39
Liu, Z. Y., Wang, J. Y., Liu, H. H., Ma, X.-M., Wang, C. L., Zhang, X. P., Tao, Y. Q., Lu, Y. C., Liao, J., & Hu, G. (2012) · Oncogene · doi:10.1038/onc.2012.155 · Cited by 38
Epigenetic alterations in human parathyroid tumors
Verdelli, C., Forno, I., Vaira, V., & Corbetta, S. (2015) · Endocrine · doi:10.1007/s12020-015-0555-4 · Cited by 37
“However, aberrant expression of RIZ1 protein was not detected in parathyroid tumors and loss of RIZ1 does not appear to be able to drive parathyroid tumor development in genetically engineered mice [11] (Table 1).”
BackgroundLei, Q., Liu, X., Fu, H., Sun, Y., Wang, L., Xu, G., Wang, W., Yu, Z., Liu, C., Li, P., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6652 · Cited by 37
“Overexpression of PRDM2 induces cell apoptosis and differentiation, possibly via H3K9 histone methylation, in CML blast crisis cell lines [7, 8].”
BackgroundChang, Y., Chang, C., Huang, H., Lin, C., Yeh, K., & Chang, J. (2018) · Endocrine Pathology · doi:10.1007/s12022-018-9543-6 · Cited by 37
Is There a Histone Code for Cellular Quiescence?
Bonitto, K., Sarathy, K., Atai, K., Mitra, M., & Coller, H. A. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.739780 · Cited by 39
“In mammals, there are multiple methyltransferases that add methyl groups to histone H3 lysine 9 including the 17 members of the PRDM family of proteins (Steele-Perkins et al., 2001; Hyun et al., 2017).”
BackgroundReid, A. G., & Nacheva, E. P. (2003) · Leukemia · doi:10.1038/sj.leu.2403162 · Cited by 36
Histone Methyltransferases in Tumor Suppression
Kim, K., & Huang, S. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.2.5.629 · Cited by 37
“Silencing/mutation, G2/M arrest (43), NM_012231 proapoptoic, binds Rb, yin-yang”
Congdon, L. M., Sims, J. K., Tuzon, C. T., & Rice, J. C. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1377 · Cited by 35
“Riz1 was originally identified as an Rb-binding protein that functions as a tumor suppressor by inducing cell cycle arrest and apoptosis (18,20).”
BackgroundGenetic background influences susceptibility to chemotherapy-induced hematotoxicity
Gatti, D. M., Weber, S. N., Goodwin, N. C., Lammert, F., & Churchill, G. A. (2017) · The Pharmacogenomics Journal · doi:10.1038/tpj.2017.23 · Cited by 33
Molecular Basis of Primary Hyperparathyroidism
Arnold, A., & Levine, M. A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-397166-1.00018-7 · Cited by 35
Human PRDM2: Structure, function and pathophysiology
Sorrentino, A., Rienzo, M., Ciccodicola, A., Casamassimi, A., & Abbondanza, C. (2018) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2018.06.002 · Cited by 37
Chromatin‐modifying proteins in cancer
Fog, C. K., Jensen, K. T., & Lund, A. H. (2007) · Apmis · doi:10.1111/j.1600-0463.2007.apm_776.xml.x · Cited by 35
Kolomietz, E., Marrano, P. M., Yee, K. W. L., Thai, B., Braude, I., Kolomietz, A., Chun, K., Minkin, S., Kamel‐Reid, S., Minden, M. D., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2402969 · Cited by 34
Context-specific regulation of cancer epigenomes by histone and transcription factor methylation
Sarris, M. E., Nikolaou, K., & Talianidis, I. (2013) · Oncogene · doi:10.1038/onc.2013.87 · Cited by 33
RIZ1: a potential tumor suppressor in glioma
Zhang, C., Zhu, Q., He, H., Jiang, L., Qiang, Q., Hu, L., Hu, G., Jiang, Y., Ding, X., & Lu, Y. (2015) · BMC Cancer · doi:10.1186/s12885-015-2023-1 · Cited by 31
Dong, S., Zhang, H., Wang, B., Sun, P., Wang, Y.-G., & Zhang, P. (2014) · Oncology Reports · doi:10.3892/or.2014.3307 · Cited by 30
Piao, G., Piao, W., He, Y., Zhang, H. H., Wang, G. Q., & Piao, Z. H. (2008) · PubMed · doi:10.14670/hh-23.1171 · Cited by 29
DNA methylation of the RIZ1 gene is associated with nuclear accumulation of p53 in prostate cancer
Hasegawa, Y., Matsubara, A., Teishima, J., Seki, M., Mita, K., Usui, T., Oue, N., & Yasui, W. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00338.x · Cited by 29
Haney, S. L., Hlady, R. A., Opavska, J., Klinkebiel, D. L., Pirruccello, S. J., Dutta, S., Datta, K., Simpson, M. A., Wu, L., & Opavský, R. (2015) · Oncogene · doi:10.1038/onc.2014.472 · Cited by 29
Metadata
- Authors
- Steele-Perkins, G., Fang, W., Yang, X.-H., Van Gele, M., Carling, T., Gu, J., Buyse, I. M., Fletcher, J. A., Liu, J., Bronson, R., Chadwick, R. B., de la Chapelle, A., Zhang, X.-K., Speleman, F., & Huang, S.
- Affiliations
- Cleveland Clinic (US)
- Tufts University (US)
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2001-09-01
- Volume
- 15
- Issue
- 17
- Pages
- 2250-2262
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- PMC
- PMC312773
- OpenAlex
- W2166083262
- Cited by
- 208
- References
- 52
- Citations by year
- 2025: 4 · 2024: 3 · 2023: 4 · 2022: 1 · 2021: 4 · 2020: 2 · 2019: 3 · 2018: 6 · 2017: 12 · 2016: 8 · 2015: 15 · 2014: 8 · 2013: 9 · 2012: 10
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Genes & Development (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Funders
- Tobacco-Related Disease Research Program
- National Institutes of Health (5r01ca076146-03)
- National Cancer Institute (CA-76146, CA60988, R01CA060988)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer-related gene regulation
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- RIZ1, PRDM2, cancer susceptibility genes, diffuse large B-cell lymphoma, carcinogenesis, microsatellite instability, frameshift mutation, missense mutations
- MeSH terms
- Alleles, Amino Acid Sequence, Animals, Base Sequence, DNA Mutational Analysis, DNA-Binding Proteins, Multigene Family, Heterozygote, Humans, Immunoglobulin Heavy Chains, Karyotyping, Models, Genetic, Molecular Sequence Data, Mutation, Neoplasms, Nuclear Proteins, Protein Binding, Histone-Lysine N-Methyltransferase, Receptors, Estrogen, Time Factors, Transcription Factors, Tumor Cells, Cultured, Blotting, Southern, Blotting, Northern, Transcriptional Activation, Genes, p53, Retinoblastoma Protein, Mutagenesis, Site-Directed, Frameshift Mutation, Protein Structure, Tertiary, Microsatellite Repeats, Genetic Predisposition to Disease, Mutation, Missense, Reverse Transcriptase Polymerase Chain Reaction, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
